Imatinib‐sensitive (TF1‐BA)44 and imatinib‐resistant (TF1‐BAR) cell models were created by Dr Voetzel in the laboratory of Dr Veronique Maguer‐Satta, as outlined in Figure 1A. To uncover the role of SETD2 in imatinib resistance development in CML, we first analysed the SETD2 expression level in the TF1, TF1‐BA and TF1‐BAR cells by Western blot and qRT‐PCR assays. This evidence concerns the gene SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive.